N-(6,7-Dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-d-aspartate receptor antagonists for the treatment of pain

Christopher Deur, Arun K. Agrawal, Heidi Baum, John Booth, Susan Bove, Joan Brieland, Amy Bunker, Cleo Connolly, Joseph Cornicelli, Jo Ann Dumin, Barry Finzel, Xinmin Gan, Sheila Guppy, Gregg Kamilar, Kenneth Kilgore, Pil Lee, Cho Ming Loi, Zhen Lou, Mark Morris, Laurence PhilippeSally Przybranowski, Frank Riley, Brian Samas, Brian Sanchez, Haile Tecle, Ziqiang Wang, Kathryn Welch, Michael Wilson, Karen Yates

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

It has been hypothesized that peripherally restricted NMDA receptor antagonists may be effective analgesics for osteoarthritis pain. A class of novel quinoxalinedione atropisomers, first discovered for an NMDA receptor antagonist program for the treatment of stroke, was evaluated and further optimized with the goal of finding peripherally restricted NMDA receptor antagonists.

Original languageEnglish (US)
Pages (from-to)4599-4603
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume17
Issue number16
DOIs
StatePublished - Aug 15 2007

Keywords

  • NMDA antagonist
  • Osteoarthritis
  • Pain

Fingerprint

Dive into the research topics of 'N-(6,7-Dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-d-aspartate receptor antagonists for the treatment of pain'. Together they form a unique fingerprint.

Cite this